The fragility index is a method to assess robustness of a clinical trial and is defined the minimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to non-significant. Among 25 randomized controlled trials in HCC, the median fragility index was 5 and ten trials among 25 (40%) had a fragility index of 2 or less indicating an important fragility.
Fragility index of positive phase II and III randomized clinical trials of treatments for hepatocellular carcinoma (2002-2022) / Sidali, Sabrina; Sritharan, Nanthara; Campani, Claudia; Gregory, Jules; Durand, François; Ganne-Carrié, Nathalie; Ronot, Maxime; Lévy, Vincent; Nault, Jean-Charles. - In: JHEP REPORTS. - ISSN 2589-5559. - STAMPA. - (2023), pp. 0-0. [10.1016/j.jhepr.2023.100755]
Fragility index of positive phase II and III randomized clinical trials of treatments for hepatocellular carcinoma (2002-2022)
Campani, Claudia;
2023
Abstract
The fragility index is a method to assess robustness of a clinical trial and is defined the minimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to non-significant. Among 25 randomized controlled trials in HCC, the median fragility index was 5 and ten trials among 25 (40%) had a fragility index of 2 or less indicating an important fragility.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2589555923000861-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
725.96 kB
Formato
Adobe PDF
|
725.96 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
